Tg Therapeutics (TGTX) Total Liabilities (2010 - 2026)

Tg Therapeutics' Total Liabilities history runs 17 years deep, the most recent figure standing at $945.7 million for Q1 2026.

• On a quarterly basis, Total Liabilities rose 125.49% year-over-year to $945.7 million in Q1 2026; TTM through Mar 2026 was $945.7 million, a 125.49% increase from a year earlier, with the FY2025 full-year figure at $415.2 million, up 16.86% from the prior year.
• Total Liabilities advanced to $945.7 million in Q1 2026 per TGTX's latest filing, from $415.2 million in the prior quarter.
• Across five years, Total Liabilities topped out at $945.7 million in Q1 2026 and bottomed at $117.4 million in Q3 2022.
• The 5-year median for Total Liabilities is $213.2 million (2024), against an average of $294.3 million.
• Across the five-year window, Total Liabilities retreated 5.26% in 2022 and surged 136.84% in 2024, its largest moves.
• Year by year, Total Liabilities stood at $135.0 million in 2022, then grew by 25.26% to $169.1 million in 2023, then surged by 110.15% to $355.3 million in 2024, then gained by 16.86% to $415.2 million in 2025, then jumped by 127.75% to $945.7 million in 2026.
• Per Business Quant, the three latest TGTX Total Liabilities figures stand at $945.7 million (Q1 2026), $415.2 million (Q4 2025), and $417.8 million (Q3 2025).